Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hyloris Pharmaceuticals SA ( (DE:52U) ) has issued an update.
Hyloris Pharmaceuticals SA announced the expiry of a warrant plan for its employees and managers, with the total share capital amounting to EUR 140,001.87. The company disclosed that there are 309,313 subscription rights granted, which will lead to the issuance of ordinary shares. This announcement reflects the company’s current financial structure and potential equity movements, which may have implications on its market positioning and investor relations.
More about Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA is a specialty biopharma company based in Liège, Belgium, focused on innovating, reinventing, and optimizing existing medications. The company leverages existing regulatory pathways like the FDA’s 505(b)2 to reduce development timelines and costs, and has a broad portfolio of reformulated and repurposed medicines, including Sotalol IV and Maxigesic® IV. Hyloris also develops high barrier generic products.
YTD Price Performance: -20.73%
Average Trading Volume: 917
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €173M
See more data about 52U stock on TipRanks’ Stock Analysis page.